BASEL, Switzerland, Oct. 6, 2025 — Roche announced that it has received CE-mark approval for the AI-based Kidney Klinrisk Algorithm, developed in collaboration with KlinRisk Inc. The algorithm, now part of Roche’s Chronic Kidney Disease (CKD) algorithm panel on the navify® Algorithm Suite, enables clinicians to assess and monitor risk of progressive kidney function decline across all disease stages, including early asymptomatic phases.

Science Significance

The Kidney Klinrisk Algorithm applies machine-learning modeling to routine blood and urine test data to predict CKD progression risk. Integrated with the Kidney KFRE Algorithm, it provides clinicians with a comprehensive AI-powered toolset for evaluating both early and advanced CKD. The innovation aims to enhance precision in risk stratification, allowing earlier intervention to delay or prevent kidney failure, a condition affecting over 700 million people globally.

Regulatory Significance

This CE-mark approval under the EU IVDR (2017/746) confirms compliance with European safety and performance standards for in vitro diagnostic medical-device software. It authorizes the Kidney Klinrisk Algorithm for clinical use in Europe and the U.K., supporting evidence-based, algorithm-driven kidney-care decisions. The approval underscores regulatory recognition of AI as a trusted clinical decision-support technology.

Business Significance

The launch expands Roche’s growing digital-health and diagnostics ecosystem. By integrating AI-driven algorithms into its navify® platform, Roche strengthens its position as a global leader in digital diagnostics. The cloud-based solution, compatible with existing hospital systems, is expected to extend to the U.S., Middle East, and Asia following regional approvals, reinforcing Roche’s commercial reach in predictive healthcare analytics.

Patients’ Significance

For patients with diabetes, hypertension, or early-stage CKD, the algorithm enables physicians to detect and manage risk before irreversible kidney damage occurs. By supporting proactive care and personalized interventions, it has the potential to reduce dialysis dependence, cardiovascular complications, and healthcare costs, improving quality of life for millions at risk.

Policy Significance

The CE-mark milestone reflects broader European and global regulatory alignment encouraging responsible deployment of AI-enabled diagnostic technologies. It highlights the importance of policy frameworks supporting digital-health innovation, interoperability, and patient data protection, including compliance with GDPR and HIPAA. Such initiatives advance the safe integration of AI into healthcare.

Roche’s CE-mark approval for the Kidney Klinrisk Algorithm represents a pivotal moment for AI in kidney-care diagnostics. By merging advanced data science with clinical precision, this regulatory success reinforces Roche’s leadership in MedTech innovation and its commitment to transforming chronic-disease management worldwide.

Source: Roche press release